What happened with ARWR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Arrowhead Research Corporation develops medicines that reduce the production of proteins involved in disease by silencing the genetic messages that cells use to make them. This approach is called RNA interference, or RNAi. Drugmakers pay Arrowhead for rights to programs it does not intend to commercialize itself. These agreements provide upfront payments and payments when development or sales milestones are reached, with royalties possible if the drugs reach the market. Reported revenue has come mainly from partner agreements, especially Sarepta, rather than drug sales.
Arrowhead is also entering commercialization with its first approved medicine, REDEMPLO (plozasiran). Its U.S. approval covers lowering triglycerides alongside diet in adults with familial chylomicronemia syndrome, a rare disease. Arrowhead expects its exclusive drug-delivery partner, Vanscoy Rare Pharmacy, to handle a substantial portion of REDEMPLO sales. Sales depend partly on government and private insurers covering treatment. Use in the broader severe-hypertriglyceridemia market remains a planned expansion requiring further approval.
Most of Arrowhead’s other medicines remain in clinical development and cannot be marketed before approval. For licensed programs, partners control much of the development and commercialization, so further payments depend on their progress and decisions as well as trial results.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Ionis Pharmaceuticals, Inc.’s TRYNGOLZA and WAYLIVRA compete with Arrowhead’s REDEMPLO for patients with familial chylomicronemia syndrome (FCS), with potential competition in severe hypertriglyceridemia too. Their patent dispute also puts REDEMPLO commercialization at risk: a successful Ionis claim could require damages, a license or abandonment of the affected medicine.
Arrowhead relies heavily on Sarepta Therapeutics’ payments for licensed gene-silencing drug programs in rare genetic diseases: the agreement generated $696.8 million of Arrowhead’s $829.448 million revenue in the year ended September 30, 2025. Watch ARO-DM1 trial progress, where enrollment and permission to raise doses have already triggered a milestone payment, with future commercial sales potentially bringing royalties.
Alnylam Pharmaceuticals and Arrowhead both develop and sell medicines that silence disease-related genes, so clinical success, delivery improvements and adoption of RNAi medicines matter to both. Arrowhead also holds a royalty-bearing license to Alnylam intellectual property for 30 undisclosed gene targets; Alnylam’s AMVUTTRA and ONPATTRO sales offer a concrete place to watch adoption of this drug approach.
Takeda co-develops fazirsiran with Arrowhead and would turn an approval into shared U.S. profits and royalties elsewhere. If approved, Arrowhead would receive half of U.S. profits and royalties of 20%–25% of net sales outside the U.S., where Takeda holds exclusive commercialization rights.
Novartis pays Arrowhead for rights to ARO-SNCA and additional programs built on its gene-silencing drug platform, providing $200 million upfront when the agreement closed in October 2025. Progress in these programs matters to Arrowhead’s eligibility for up to $2 billion in potential milestone payments, plus royalties on commercial sales.
Amgen controls development and commercialization of Arrowhead’s licensed olpasiran, so its trial, regulatory and sales progress determines Arrowhead’s remaining milestone opportunities. Arrowhead remains eligible for up to $485 million from Amgen and Royalty Pharma, but all olpasiran royalties otherwise owed to Arrowhead now go to Royalty Pharma.
Arrowhead depends on GSK to develop and commercialize its licensed hepatitis B program worldwide and its HSD17B13 program outside Greater China. Watch the hepatitis B candidate daplusiran/tomligisiran’s trial progress: dosing the fifth patient in Phase 2 in December 2024 triggered a $2.5 million payment to Arrowhead.
Sanofi’s purchase of plozasiran assets and Greater China development and commercialization rights from Visirna generated $130 million of Arrowhead’s revenue in the year ended September 30, 2025. Sanofi’s regional development progress now matters to the same medicine Arrowhead sells in the U.S. as REDEMPLO for adults with FCS.
Wave Life Sciences’ approach of editing RNA to treat alpha-1 antitrypsin deficiency (AATD) competes with Arrowhead’s fazirsiran, while both companies build platforms for multiple RNA medicines. Watch Wave’s AATD clinical results as evidence of how a different RNA approach could compete with fazirsiran.
ADARx Pharmaceuticals competes with Arrowhead in kidney disease and obesity programs, and both develop siRNA medicines that silence genes while seeking to reach tissues beyond the liver. Watch ADARx’s obesity candidate targeting fat tissue for evidence of progress in this shared delivery challenge.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda’s report can show how fazirsiran is progressing; if approved, Takeda and Arrowhead would split the drug’s U.S. profits.
Look for Takeda’s update on fazirsiran’s clinical development and next steps. Clear progress would strengthen the path toward a 50/50 U.S. profit share and royalties of 20% to 25% of net sales outside the United States; stalled development would leave those potential returns dependent on approvals and sales still to come. The conclusion is whether this collaboration is closer to generating product income or further away.
Sanofi earningsSNY
Sanofi’s report can show whether plozasiran is progressing in Greater China, offering a regional read on the same medicine Arrowhead sells in the United States.
Look for concrete updates on plozasiran’s development, approval, or commercialization in Greater China. It is the same medicine as REDEMPLO, which Arrowhead sells in the United States, but the market and rights holder differ. Clear progress would show the regional license may extend the medicine’s reach; without it, Arrowhead’s U.S. sales do not establish that the Greater China market is opening too. The question is whether the drug is making tangible headway beyond the U.S.
Sarepta Therapeutics,, Inc. earningsSRPT
Sarepta’s report will show whether progress in ARO-DM1 continues to support opportunities for milestone payments to Arrowhead.
Look for ARO-DM1 trial progress and any newly achieved milestone, then read that against Arrowhead’s disclosures on Sarepta-related revenue and cash. Advancing trials that trigger a payment would show this major collaboration still converting into funding; little progress or no new payment would mean less evidence that it can keep replenishing Arrowhead’s development resources.
Ionis Pharmaceuticals, Inc. earningsIONS
Ionis Pharmaceuticals, Inc.’s report can show whether its FCS drugs are competing for the same patients as Arrowhead’s REDEMPLO.
Look at sales or patient uptake for Ionis’s TRYNGOLZA and WAYLIVRA alongside Arrowhead’s disclosures on REDEMPLO sales and market reach. Greater uptake of Ionis’s drugs would show competitors capturing some FCS demand; limited uptake would mean less evidence of that pressure, not an absence of other commercial risks for REDEMPLO. Ionis’s sales cannot settle the patent case; the read-through is how intense the fight for FCS patients appears.
Wave Life Sciences Ltd. earningsWVE
Wave Life Sciences Ltd.’s report can show how its RNA-editing approach for AATD is progressing and what competition it may pose to Arrowhead’s fazirsiran.
Look at Wave’s AATD clinical data and trial progress, bearing in mind that fazirsiran also targets AATD. Convincing results or progress would make another RNA-based approach a more credible future competitor; limited data or progress would weaken the evidence for that competitive path, but would not establish that fazirsiran will succeed. The question is whether this alternative is drawing closer or remains at an earlier stage.
Arrowhead Research Corporation earningsThis company
Arrowhead’s report will show whether REDEMPLO sales are starting to complement partner payments in funding its drug development and commercialization costs.
Read REDEMPLO product sales and collaboration revenue alongside cash from operating activities. Rising product sales with operating cash holding up would show commercial revenue beginning to complement partner payments. If recognized revenue still comes mainly from collaborations and operating cash weakens, development and commercialization remain more dependent on partner funding. The question is whether Arrowhead’s funding base is becoming more recurring and more supported by its own product.
